Interim Safety of RSVpreF Vaccination During Pregnancy

Ashley I. Michnick; Sarah C. MacDonald; Austin Cosgrove; Sruthi Adimadhyam; Fang Zhang; Andrew B. Petrone; Katherine E. Round; Sampada Gandhi; Nana Koram; Olympia E. Anastasiou; Heather Rubino; Maria Maddalena Lino; Djeneba Audrey Djibo; Kuntz Jl; S B Love; Cheryl N. McMahill‐Walraven; Kristin Palmsten; Anna E. Wentz; Judith C. Maro; Richard Platt; Susan E. Andrade

doi:10.1001/jama.2025.23452

Abstract

This is the authors' abstract. We don't add key points for this paper.

This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Michnick et al. (2026) studied this question.

synapsesocial.com/papers/6aae5767d7edda362b0ccd6d https://doi.org/10.1001/jama.2025.23452

View Full Paper

Ask AI

Bookmark

Share

Interim Safety of RSVpreF Vaccination During Pregnancy

Abstract

Ask about this paper

Discussion

Cite This Study

Interim Safety of RSVpreF Vaccination During Pregnancy

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading